Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CUDC-907

Known as: PI3K/HDAC Inhibitor CUDC-907 
An orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract CUDC‐907, a dual PI3K/HDAC inhibitor, has been proposed to have therapeutic potential in hematopoietic malignancies… Expand
  • figure 2
Is this relevant?
2018
2018
Aberrant chromatin remodeling and activation of the PI3K pathway have been identified as important mediators of pediatric high… Expand
Is this relevant?
2017
2017
CUDC-907 is a first-in-class, oral small molecule inhibitor of both HDAC (class I and II) and PI3K (class Iα, β, and δ) enzymes… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2017
2017
The role of bone marrow adipocytes (BMAs) in overall energy metabolism and their effects on bone mass are currently areas of… Expand
Is this relevant?
2017
2017
Purpose: There is currently no standard therapy for anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer… Expand
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
SummaryPlatinum (Pt)-based anticancer drugs are the mainstay of treatment for solid cancers. However, resistance to Pt drugs… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited. CUDC-907 is an… Expand
Is this relevant?
2016
2016
Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs… Expand
Is this relevant?
2016
2016
CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?